X4 Pharmaceuticals, Inc. (XFOR)
XFOR Stock Price Chart
Explore X4 Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze XFOR price movements and trends.
XFOR Company Profile
Discover essential business fundamentals and corporate details for X4 Pharmaceuticals, Inc. (XFOR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Nov 2017
Employees
143.00
Website
https://www.x4pharma.comCEO
Adam R. Craig
Description
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
XFOR Financial Timeline
Browse a chronological timeline of X4 Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.19, while revenue estimate is $2.42m.
Earnings released on 6 May 2026
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%, while revenue for the quarter reached $2.71m , missing expectations by -15.38%.
Earnings released on 17 Mar 2026
EPS came in at -$0.22 surpassing the estimated -$0.36 by +38.89%, while revenue for the quarter reached $2.57m , beating expectations by +48.18%.
Earnings released on 5 Nov 2025
EPS came in at -$0.69 surpassing the estimated -$0.79 by +12.66%, while revenue for the quarter reached $1.77m , beating expectations by +1.85%.
Earnings released on 8 Aug 2025
EPS came in at -$3.47 surpassing the estimated -$4.53 by +23.40%, while revenue for the quarter reached $1.97m , missing expectations by -11.38%.
Earnings released on 1 May 2025
EPS came in at $0.04 surpassing the estimated -$4.13 by +100.97%, while revenue for the quarter reached $28.81m , beating expectations by +1.42k%.
Stock split effective on 28 Apr 2025
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 25 Mar 2025
EPS came in at -$6.01 falling short of the estimated -$5.11 by -17.61%, while revenue for the quarter reached $1.43m , missing expectations by -35.82%.
Earnings released on 13 Nov 2024
EPS came in at -$0.18 falling short of the estimated -$0.17 by -5.88%, while revenue for the quarter reached $560.00k , missing expectations by -44.97%.
Earnings released on 8 Aug 2024
EPS came in at -$0.07 falling short of the estimated -$0.05 by -40.00%, while revenue for the quarter reached $563.00k , beating expectations by +101.07%.
Earnings released on 7 May 2024
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%.
Earnings released on 21 Mar 2024
EPS came in at -$0.10 surpassing the estimated -$0.15 by +33.33%, while revenue for the quarter reached $3.06m .
Earnings released on 9 Nov 2023
EPS came in at -$0.01 surpassing the estimated -$0.15 by +93.33%.
Earnings released on 10 Aug 2023
EPS came in at -$0.33 falling short of the estimated -$0.17 by -94.12%.
Earnings released on 4 May 2023
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%.
Earnings released on 21 Mar 2023
EPS came in at -$0.29 falling short of the estimated -$0.23 by -26.09%.
Earnings released on 3 Nov 2022
EPS came in at -$0.26 surpassing the estimated -$0.31 by +16.13%.
Earnings released on 4 Aug 2022
EPS came in at -$0.60 surpassing the estimated -$0.65 by +7.69%.
Earnings released on 12 May 2022
EPS came in at -$0.72 falling short of the estimated -$0.62 by -16.13%.
Earnings released on 17 Mar 2022
EPS came in at -$1.24 falling short of the estimated -$0.68 by -82.35%.
Earnings released on 4 Nov 2021
EPS came in at -$0.76 falling short of the estimated -$0.72 by -5.56%.
Earnings released on 3 Aug 2021
EPS came in at -$0.74 falling short of the estimated -$0.73 by -1.37%.
XFOR Stock Performance
Access detailed XFOR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
